MDA Space (MDA) Q3 2026 Earnings Call Transcript

MDA Space reported Q3 2026 revenue of CAD 498 million, up 22% year over year, and adjusted EBITDA of CAD 96 million, up 16%; adjusted EBITDA margin eased to 19.3% from 20.2%. The company raised 2026 revenue guidance to CAD 1.9–1.95 billion from CAD 1.8–1.9 billion and adjusted EBITDA guidance to CAD 355–375 million from CAD 330–370 million, citing year-to-date execution. Backlog was about CAD 4 billion, including CAD 1.4 billion for Telesat Lightspeed, and management cited a CAD 40 billion opportunity pipeline. Pending Blue Canyon Technologies and CLS acquisitions could contribute nearly CAD 700 million of pro forma 2026 revenue, but remain subject to approvals and closing conditions.

Analysis

MDA’s quarter supports a shift from “promising backlog” toward demonstrated prime-contractor delivery, but not yet a clean margin or cash-conversion re-rating. Revenue growth is outpacing EBITDA growth, with management attributing lower margins to mix and scaling investment; that makes incremental program mix and SG&A discipline more important than headline growth over the next few quarters. The equity-funded liquidity also should not be treated as surplus cash: acquisitions consume most of it, while share issuance has already diluted per-share earnings growth. Pro forma acquisition revenue is not evidence of accretion until closing, integration costs, and cash contribution are visible.

The second-order risk is program timing versus reported execution. MDA says its Lightspeed hardware remains on plan, but Telesat’s software/network schedule and launch access can defer customer deployment without immediately stopping MDA’s production revenue. With no large Pathfinder milestone payments, schedule slippage may show up first in working capital and cash conversion rather than a sudden revenue miss. Conversely, CHORUS and Globalstar delivery validate capability, but repeatable yields, customer conversion from letters of intent, and recurring-data economics remain unproven. The large opportunity pipeline is not contracted demand; backlog replacement and conversion matter more.

Near term, guidance raised on execution is supportive, but avoid paying up before the market tests the margin and cash-flow implications. Over 1–3 months, acquisition close announcements and Q4 execution are catalysts; the March 2027 plan is the key test of organic growth, margin floor, and free-cash-flow recovery. Over 6–18 months, successful integration and CHORUS commercialization could broaden recurring revenue and reduce reliance on hardware programs. Thesis weakens if backlog continues to contract without replacement, EBITDA margin falls below the guided range, acquisitions slip materially, or working-capital consumption persists into 2027.

Key Decisions for Investors

• MDA (TSX): constructive, but do not chase the guidance raise without valuation context. Prefer staged entry on post-results weakness; add only if Q4 delivery holds the 18%–20% adjusted EBITDA margin range and March guidance supports organic growth with a credible cash-conversion path. Falsifier: margin below range or another material deterioration in free cash flow.
• Track acquisition closes as separate catalysts, not as immediate earnings upgrades. Verify purchase consideration/funding, closing dates, integration costs, and acquired-company cash generation before underwriting the stated pro forma revenue or recurring-revenue uplift.
• Watch Telesat’s Lightspeed schedule and MDA working capital together. A schedule delay is not automatically an MDA revenue thesis break, but a worsening MDA cash-conversion trend alongside delayed program milestones would justify reducing exposure. No launch-capacity short is warranted on management’s monitoring comment alone.
• Keep CHORUS commercialization on a confirmation list: look for signed contracts replacing letters of intent, customer mix, and evidence that data/services contribute recurring economics. If launches and customer conversion slip, the valuation case based on vertical integration should be deferred rather than extrapolated.